In a first aspect, the invention provides fully human mono-
clonal antibodies (mAbs) and antigen-binding fragments
thereof that specifically bind and neutralize human PCSK9
(hPCSK9) activity.;[noData]

In one embodiment, the invention comprises an antibody or
antigen-binding fragment of an antibody that specifically
binds hPCSK9 and is characterized by at least one of:
(I) capable of reducing serum total cholesterol at least
about 25-35% and sustaining the reduction over at least a 24
day period relative to a predo se level, preferably the reduction
in serum total cholesterol is at least about 30-40%;;[noData]

(ii) capable of reducing serum LDL cholesterol at least
about 65-80% and sustaining the reduction over at least a 24
day period relative to a predose level;;[noData]

(iii) capable of reducing serum triglyceride at least about
25-40% relative to predose level;;[noData]

5
10
15
20
25
30
35
40
45
50
55
60
65
(iv) does not reduce serum HDL cholesterol or reduces
serum HDL cholesterol no more than 5% relative to predose
level.;[noData]

In one embodiment, the invention comprises an antibody or
antigen-binding fragment of an antibody that specifically
binds hPCSK9 and is characterized by at least one of:
(I) capable of reducing serum LDL cholesterol at least
about 40-70% and sustaining the reduction over at least a 60
or 90 day period relative to a predose level;;[noData]

(ii) capable of reducing serum triglyceride at least about
25-40% relative to predose level;;[noData]

(iii) does not reduce serum HDL cholesterol or reduces
serum HDL cholesterol no more than 5% relative to predose
level.;[noData]

In one embodiment, the antibody or antigen-binding frag-
ment is characterized as binding an epitope comprising amino
acid residue 238 of hPCSK9 (SEQ ID NO:755).;[238, 755]

In a more
specific embodiment, the antibody or antigen-binding frag-
ment binds an epitope comprising one or more of amino acid
residue 238, 153, 159 and 343 of hPCSK9 (SEQ ID NO:
755).).;[238, 153, 159, 343, 755]

In a more specific embodiment, the antibody or frag-
ment thereof is characterized as binding an epitope which
does not comprise an amino acid residue at position 192, 194,
197 and/or 237 of SEQ ID NO:755.;[noData]

In one embodiment, the antibody or antigen-binding frag-
ment is characterized as binding an epitope comprising amino
acid residue 366 of hPCSK9 (SEQ ID NO:755).;[366, 755]

In a more
specific embodiment, the antibody or antigen-binding frag-
ment binds an epitope comprising one or more of amino acid
residue at position 147, 366 and 380 of SEQ ID NO:755.;[147, 366, 380, 755]

In a
more specific embodiment, the antibody or antigen-binding
fragment of an antibody is characterized as binding an
epitope which does not comprise an amino acid residue at
position 215 or 238 of SEQ ID NO:755.;[noData]

In one embodiment, the antibody or antigen-binding frag-
ment is characterized as exhibiting an enhanced binding
affinity (K~) for hPCSK9 at pH 5.5 relative to the K~ at pH
7.4, as measured by plasmon surface resonance.;[noData]

In a specific
embodiment, the antibody or fragment thereof exhibits at
least a 20-fold, at least a 40-fold or at least a 50-fold enhanced
affinity for PCSK9 at an acidic pH relative to a neutral pH, as
measured by surface plasmon resonance.;[noData]

In one embodiment, the antibody or antigen-binding frag-
ment is characterized as not exhibiting an enhanced binding
affinity for PCSK9 at an acidic pH relative to a neutral pH, as
measured by surface plasmon resonance.;[noData]

In a specific
embodiment, the antibody or fragment thereof exhibits a
decreased binding affinity at an acidic pH.;[noData]

In another embodiment, the antibody or antigen-binding
fragment binds human, human GOF mutation D374Y, cyno-
molgus monkey, rhesus monkey, mouse, rat and hamster
PCSK9.;[noData]

In one embodiment, the antibody or antigen-binding frag-
ment binds human and monkey PCSK9, but does not bind
mouse, rat or hamster PCSK9.;[noData]

The mAbs can be full-length (, an IgGI or IgG4 antibody)
or may comprise only an antigen-binding portion (, a Fab,
F(ab')~ or scFv fragment), and may be modified to affect
functionality, e.g.;[noData]

, to eliminate residual effector functions
(Reddy et al.;[noData]

(2000) J.;[noData]

Immunol.;[noData]

164:1925-1933).;[noData]

In one embodiment, the invention comprises an antibody or
antigen-binding fragment of an antibody comprising a heavy
chain variable region (HCVR) selected from the group con-
sisting of SEQ ID NO:2, 18, 22, 26, 42, 46, 50, 66, 70, 74, 90,
94, 98, 114, 118, 122, 138, 142, 146, 162, 166, 170, 186, 190,
194, 210, 214, 218, 234, 238, 242, 258, 262, 266, 282, 286,
290, 306, 310, 314, 330, 334, 338, 354, 358, 362, 378, 382,
US 8,357,371 B2
386, 402, 406, 410, 426, 430, 434, 450, 454, 458, 474, 478,
482, 498, 502, 506, 522, 526, 530, 546, 550, 554, 570, 574,
578, 594, 598, 602, 618, 622, 626, 642, 646, 650, 666, 670,
674, 690, 694, 698, 714, 718, 722, 738 and 742, or a substan-
tially similar sequence thereof having at least 90%, at least
95%, at least 98% or at least 99% sequence identity.;[noData]

In one
embodiment, the HCVR comprises an amino acid sequence
selected from the group consisting of SEQ ID NO:50, 66, 70,
74, 90, 94, 122, 138, 142, 218, 234, 238, 242, 258, 262, 314,
330 and 334.;[noData]

In a more specific embodiment, the HCVR
comprises SEQ ID NO:90 or 218.;[noData]

In one embodiment, the antibody or fragment thereof fur-
ther comprises a light chain variable region (LCVR) selected
from the group consisting of SEQ ID NO:10, 20, 24, 34, 44,
48, 58, 68, 72, 82, 92, 96, 106, 116, 120, 130, 140, 144, 154,
164, 168, 178, 188, 192, 202, 212, 216, 226, 236, 240, 250,
260, 264, 274, 284, 288, 298, 308, 312, 322, 332, 336, 346,
356, 360, 370, 380, 384, 394, 404, 408, 418, 428, 432, 442,
452, 456, 466, 476, 480, 490, 500, 504, 514, 524, 528, 538,
548, 552, 562, 572, 576, 586, 596, 600, 610, 620, 624, 634,
644, 648, 658, 668, 672, 682, 692, 696, 706, 716, 720, 730,
740 and 744, or a substantially similar sequence thereof hav-
ing at least 90%, at least 95%, at least 98% or at least 99%
sequence identity.;[noData]

In one embodiment, the LCVR comprises
an amino acid sequence selected from the group consisting of
SEQ ID NO: 58, 68, 72, 82, 92, 96, 130, 140, 144, 226, 236,
240, 250, 260, 264, 322, 332 and 336.;[noData]

In a more specific
embodiment, the LCVR comprises SEQ ID NO:92 or 226.;[noData]

In specific embodiments, the antibody or fragment thereof
comprises a HCVR and LCVR (HCVR/LCVR) sequence
pair selected from the group consisting of SEQ ID NO: 2/10,
18/20, 22/24, 26/34, 42/44, 46/48, 50/58, 66/68, 70/72, 74/82,
90/92, 94/96, 98/106, 114/116, 118/120, 122/130, 138/140,
142/144, 146/154, 162/164, 166/168, 170/178, 186/188, 190/
192, 194/202, 210/212, 214/216, 218/226, 234/236, 238/240,
242/250, 258/260, 262/264, 266/274, 282/284, 286/288, 290/
298, 306/308, 310/312, 314/322, 330/332, 334/336, 338/346,
354/356, 358/360, 362/370, 378/380, 382/384, 386/394, 402/
404, 406/408, 410/418, 426/428, 430/432, 434/442, 450/452,
454/456, 458/466, 474/476, 478/480, 482/490, 498/500, 502/
504, 506/514, 522/524, 526/528, 530/538, 546/548, 550/552,
554/562, 570/572, 574/576, 578/586, 594/596, 598/600, 602/
610, 618/620, 622/624, 626/634, 642/644, 646/648, 650/658,
666/668, 670/672, 674/682, 690/692, 694/696, 698/706, 714/
716, 718/720, 722/730, 738/740 and 742/744.;[noData]

In one embodi-
ment, the HCVR and LCVR sequence pair comprises one of
SEQ ID NO: 50/58, 66/68, 70/72, 74/82, 90/92, 94/96, 122/
130, 138/140, 142/144, 218/226, 234/236, 238/240, 242/250,
258/260, 262/264, 314/322, 330/332 and 334/336.;[noData]

In a more
specific embodiment, the HCVR/LCVR pair comprises SEQ
ID NO:90/92 or 218/226.;[noData]

In a second aspect, the invention features an antibody or
antigen-binding fragment of an antibody comprising a heavy
chain CDR3 (HCDR3) domain selected from the group con-
sisting of SEQ ID NO:8, 32, 56, 80, 104, 128, 152, 176, 200,
224, 248, 272, 296, 320, 344, 368, 392, 416, 440, 464, 488,
512, 536, 560, 584, 608, 632, 656, 680, 704 and 728, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity;;[noData]

and
a light chain CDR3 (LCDR3) domain selected from the group
consisting of SEQ ID NO:16, 40, 64, 88, 112, 136, 160, 184,
208, 232, 256, 280, 304, 328, 352, 376, 400, 424, 448, 472,
496, 520, 544, 568, 592, 616, 640, 664, 688, 712 and 736, or
substantially similar sequences thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity.;[noData]

In
one embodiment, the HCDR3/LCDR3 sequence pair is
selected from the group consisting of SEQ ID NO:56/64,
5
10
15
20
25
30
35
40
45
50
55
60
65
80/88, 128/136, 224/232, 248/256 and 320/328.;[noData]

In a more
specific embodiment, the HCDR3/LCDR3 sequence pair
comprises SEQ ID NO:80/88 or 224/232.;[noData]

In a further embodiment, the invention comprising an anti-
body or fragment thereof further comprising a heavy chain
CDRI (HCDRI) domain selected from the group consisting
of SEQ ID NO:4, 28, 52, 76, 100, 124, 148, 172, 196, 220,
244, 268, 292, 316, 340, 364, 388, 412, 436, 460, 484, 508,
532, 556, 580, 604, 628, 652, 676, 700 and 724, or a substan-
tially similar sequence thereof having at least 90%, at least
95%, at least 98% or at least 99% sequence identity;;[noData]

a heavy
chain CDR2 (HCDR2) domain selected from the group con-
sisting of SEQ ID NO:6, 30, 54, 78, 102, 126, 150, 174, 198,
222, 246, 270, 294, 318, 342, 366, 390, 414, 438, 462, 486,
510, 534, 558, 582, 606, 630, 654, 678, 702 and 726, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity;;[noData]

a
light chain CDRI (LCDRI) domain selected from the group
consisting of SEQ ID NO:12, 36, 60, 84, 108, 132, 156, 180,
204, 228, 252, 276, 300, 324, 348, 372, 396, 420, 444, 468,
492, 516, 540, 564, 588, 612, 636, 660, 684, 708 and 732, or
a substantially similar sequence thereof having at least 90%,
at least 95%, at least 98% or at least 99% sequence identity;;[noData]

and a light chain CDR2 (LCDR2) domain selected from the
group consisting of SEQ ID NO:14, 38, 62, 86, 110, 134, 158,
182, 206, 230, 254, 278, 302, 326, 350, 374, 398, 422, 446,
470, 494, 518, 542, 566, 590, 614, 638, 662, 686, 710and734,
or a substantially similar sequence thereof having at least
90%, at least 95%, at least 98% or at least 99% sequence
identity.;[noData]

In one embodiment, the heavy and light chain CDR
sequences comprise a sequence selected from the group con-
sisting ofSEQ ID NO:52, 54, 56, 60, 62, 64;;[noData]

76, 78, 80, 84, 86,
88;;[noData]

124, 126, 128, 132, 134, 136;;[noData]

220, 222, 224, 228, 230,
232;;[noData]

244, 246, 248, 252, 254, 256;;[noData]

and 316, 318, 320, 324,
326, 328.;[noData]

In more specific embodiments, the CDR sequences
comprise SEQ ID NO: 76, 78, 80, 84, 86, 88;;[noData]

or 220, 222, 224,
228, 230, 232.;[noData]

In a related embodiment, the invention comprises an anti-
body or antigen-binding fragment of an antibody which spe-
cifically binds hPCSK9, wherein the antibody or fragment
comprises heavy and light chain CDR domains contained
within heavy and light chain sequence pairs selected from the
group consisting of SEQ ID NO: 2/10, 18/20, 22/24, 26/34,
42/44, 46/48, 50/58, 66/68, 70/72, 74/82, 90/92, 94/96,
98/106, 114/116, 118/120, 122/130, 138/140, 142/144, 146/
154, 162/164, 166/168, 170/178, 186/188, 190/192, 194/202,
210/212, 214/216, 218/226, 234/236, 238/240, 242/250, 258/
260, 262/264, 266/274, 282/284, 286/288, 290/298, 306/308,
310/312, 314/322, 330/332, 334/336, 338/346, 354/356, 358/
360, 362/370, 378/380, 382/384, 386/394, 402/404, 406/408,
410/418, 426/428, 430/432, 434/442, 450/452, 454/456, 458/
466, 474/476, 478/480, 482/490, 498/500, 502/504, 506/514,
522/524, 526/528, 530/538, 546/548, 550/552, 554/562, 570/
572, 574/576, 578/586, 594/596, 598/600, 602/610, 618/620,
622/624, 626/634, 642/644, 646/648, 650/658, 666/668, 670/
672, 674/682, 690/692, 694/696, 698/706, 714/716, 718/720,
722/730, 738/740 and 742/744.;[noData]

In one embodiment, the CDR
sequences are contained within HCVR and LCVR selected
from the amino acid sequence pairs of SEQ ID NO: 50/58,
66/68, 70/72, 74/82, 90/92, 94/96, 122/130, 138/140, 142/
144, 218/226, 234/236, 238/240, 242/250, 258/260, 262/264,
314/322, 330/332 and 334/336.;[noData]

In more specific embodi-
ments, the CDR sequences are comprised within HCVR/
LCVR sequences selected from SEQ ID NO: 90/92 or 218/
226.;[noData]

In one embodiment, the invention provides fully human
monoclonal antibody or antigen-binding fragment thereof
US 8,357,371 B2
that specifically bind hPCSK9 and neutralize PCSK9 activity,
wherein the antibody or fragment thereof exhibits one or
more of the following characteristics: (I) capable of reducing
serum total cholesterol at least about 25-35% and sustaining
the reduction over at least a 24 day period relative to a predo se
level, preferably the reduction in serum total cholesterol is at
least about 30-40%;;[noData]

(ii) capable of reducing serum LDL
cholesterol at least about 65-80% and sustaining the reduc-
tion over at least a 24 day period relative to a predose level;;[noData]

(iii) capable of reducing serum triglyceride at least about
25-40% relative to predose level;;[noData]

(iv) does not reduce serum
HDL cholesterol or reduces serum HDL cholesterol no more
than 5% relative to predose level;;[noData]

(v) binds an epitope com-
prising amino acid residue 238 of hPCSK9 (SEQ ID
NO:755);;[noData]

(vi) exhibits an enhanced binding affinity (K~) for
hPCSK9 at p H 5.5 relative to the K~ at p H 7.4, as measured by
plasmon surface resonance, wherein the enhanced affinity is
at least about a 20- to 50-fold increase in afiinity;;[noData]

(vii) binds
human, human GOF mutation D374Y, cynomolgus monkey,
rhesus monkey, mouse, rat and hamster PCSK9;;[noData]

(viii) com-
prises heavy and light chain CDR3 sequences comprising
SEQ ID NO:80 and 88;;[noData]

and (ix) comprises CDR sequences
from SEQ ID NO:90 and 92.;[noData]

In one embodiment, the invention provides fully human
monoclonal antibody or antigen-binding fragment thereof
that specifically bind human PCSK9 (hPCSK9) and neutral-
ize PCSK9 activity, wherein the antibody or fragment thereof
exhibits one or more of the following characteristics: (I)
capable of reducing serum LDL cholesterol at least about
40-70% and sustaining the reduction over at least a 60 or 90
day period relative to a predose level;;[noData]

(ii) capable of reducing
serum triglyceride at least about 25-40% relative to predose
level;;[noData]

(iii) does not reduce serum HDL cholesterol or reduces
serum HDL cholesterol no more than 5% relative to predose
level;;[noData]

(iv) binds an epitope comprising amino acid residue
366 of hPCSK9 (SEQ ID NO:755);;[366, 755]

(v) does not exhibit an
enhanced binding affinity for PCSK9 at an acidic pH relative
to a neutral pH, as measured by surface plasmon resonance;;[noData]

(vi) binds human and monkey PCSK9, but does not bind
mouse, rat or hamster PCSK9;;[noData]

(vii) comprises heavy and light
chain CDR3 sequences comprising SEQ ID NO:224 and 232;;[noData]

and (viii) comprises CDR sequences from SEQ ID NO:218
and 226.;[noData]

In a third aspect, the invention provides nucleic acid mol-
ecules encoding anti-PCSK9 antibodies or fragments thereof.;[noData]

Recombinant expression vectors carrying the nucleic acids of
the invention, and host cells into which such vectors have
been introduced, are also encompassed by the invention, as
are methods ofproducing the antibodies by culturing the host
cells under conditions permitting production of the antibod-
ies, and recovering the antibodies produced.;[noData]

In one embodiment, the invention provides an antibody or
fragment thereof comprising a HCVR encoded by a nucleic
acid sequence selected from the group consisting of SEQ ID
NO: I, 17, 21, 25, 41, 45, 49, 65, 69, 73, 89, 93, 97, 113, 117,
121, 137, 141, 145, 161, 165, 169, 185, 189, 193, 209, 213,
217, 233, 237, 241, 257, 261, 265, 281, 285, 289, 305, 309,
313, 329, 333, 337, 353, 357, 361, 377, 381, 385, 401, 405,
409, 425, 429, 433, 449, 453, 457, 473, 477, 481, 497, 501,
505, 521, 525, 529, 545, 549, 553, 569, 573, 577, 593, 597,
601, 617, 621, 625, 641, 645, 649, 665, 669, 673, 689, 693,
697, 713, 717, 721, 737 and 741, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or at
least 99%homology thereof.;[noData]

In one embodiment, the HCVR
is encoded by a nucleic acid sequence selected from the group
consisting of SEQ ID NO: 49, 65, 69, 73, 89, 93, 121, 137,
141, 217, 233, 237, 241, 257, 261, 313,329 and 333.In more
5
10
15
20
25
30
35
40
45
50
55
60
65
specific embodiments, the HCVR is encoded by a nucleic
acid sequence selected from the group consisting of SEQ ID
NO: 89 and 217.;[noData]

In one embodiment, the antibody or fragment thereof fur-
ther comprises a LCVR encoded by a nucleic acid sequence
selected from the group consisting of SEQ ID NO: 9, 19, 23,
33, 43, 47, 57, 67, 71, 81, 91,95, 105, 115,119,129, 139, 143,
153, 163, 167, 177, 187, 191, 201, 211, 215, 225, 235, 239,
249, 259, 263, 273, 283, 287, 297, 307, 311,321, 331, 335,
345, 355, 359, 369, 379, 383, 393, 403, 407, 417, 427, 431,
441, 451, 455, 465, 475, 479, 489, 499, 503, 513, 523, 527,
537, 547, 551, 561, 571, 575, 585, 595, 599, 609, 619, 623,
633, 643, 647, 657, 667, 671, 681, 691, 695, 705, 715, 719,
729, 739 and 743, or a substantially identical sequence having
at least 90%, at least 95%, at least 98%, or at least 99%
homology thereof.;[noData]

In one embodiment, the LCVR is encoded
by a nucleic acid sequence selected from the group consisting
ofSEQ ID NO: 57, 67, 71, 81, 91, 95, 129, 139, 143, 225, 235,
239, 249, 259, 263, 321, 331 and 335.;[noData]

In more specific
embodiments, the LCVR is encoded by a nucleic acid
sequence selected from the group consisting of SEQ ID NO:
91 and 225.;[noData]

In one embodiment, the invention features an antibody or
antigen-binding fragment of an antibody comprising a
HCDR3 domain encoded by a nucleotide sequence selected
from the group consisting of SEQ ID NO:7, 31, 55, 79, 103,
127, 151, 175, 199, 223, 247, 271, 295, 319, 343, 367, 391,
415, 439, 463, 487, 511, 535, 559, 583, 607, 631, 655, 679,
703 and 727, or a substantially identical sequence having at
least 90%, at least 95%, at least 98%, or at least 99%homol-
ogy thereof;;[noData]

and a LCDR3 domain encoded by a nucleotide
sequence selected from the group consisting of SEQ ID NO:
15, 39, 63, 87, 111, 135, 159, 183, 207, 231, 255, 279, 303,
327, 351, 375, 399, 423, 447, 471, 495, 519, 543, 567, 591,
615, 639, 663, 687, 711 and 735, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or at
least 99% homology thereof.;[noData]

In one embodiment, the
HCDR3 and LCDR3 comprise a sequence pair encoded by
the nucleic acid sequence of SEQ ID NO: 55/63, 79/87,
127/135, 223/231, 247/255 and 319/327, respectively.;[noData]

In
more specific embodiments, the HCDR3 and LCDR3 com-
prise a sequence pair encoded by the nucleic acid sequence of
SEQ ID NO: 79/87 and 223/231.;[noData]

In a further embodiment, the antibody or fragment thereof
further comprises, a HCDRI domain encoded by a nucleotide
sequence selected from the group consisting of SEQ ID NO:
3, 27, 51, 75, 99, 123, 147, 171, 195, 219, 243, 267, 291, 315,
339, 363, 387, 411, 435, 459, 483, 507, 531, 555, 579, 603,
627, 651, 675, 699 and 723, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or at
least 99%homology thereof;;[noData]

a HCDR2 domain encoded by a
nucleotide sequence selected from the group consisting of
SEQ ID NO:5, 29, 53, 77, 101, 125, 149, 173, 197, 221, 245,
269, 293, 317, 341, 365, 389, 413, 437, 461, 485, 509, 533,
557, 581, 605, 629, 653, 677, 701 and 725, or a substantially
identical sequence having at least 90%, at least 95%, at least
98%, or at least 99% homology thereof;;[noData]

a LCDRI domain
encoded by a nucleotide sequence selected from the group
consisting of SEQ ID NO: 11,35, 59, 83, 107, 131, 155, 179,
203, 227, 251, 275, 299, 323, 347, 371, 395, 419, 443, 467,
491, 515, 539, 563, 587, 611, 635, 659, 683;;[noData]

707 and 731, or
a substantially identical sequence having at least 90%, at least
95%, at least 98%, or at least 99% homology thereof;;[noData]

and a
LCDR2 domain encoded by a nucleotide sequence selected
from the group consisting of SEQ ID NO: 13, 37, 61, 85, 109,
133, 157, 181, 205, 229, 253, 277, 301, 325, 349, 373, 397,
421, 445, 469, 493, 517, 541, 565, 589, 613, 637, 661, 685,
US 8,357,371 B2
709 and 733, or a substantially identical sequence having at
least 90%, at least 95%, at least 98%, or at least 99%homol-
ogy thereof.;[noData]

In one embodiment, the heavy and light chain
CDR sequences are encoded by the nucleic acid sequences of
SEQ ID NO: 51, 53, 55, 59, 61, 63;;[noData]

75, 77, 79, 83, 85, 87;;[noData]

123,
125, 127, 131, 133, 135;;[noData]

219, 221, 223, 227, 229, 231;;[noData]

243,
245, 247, 251, 253, 255;;[noData]

and315, 317,319,323, 325, 327.;[noData]

In
more specific embodiments, the heavy and light chain CDR
sequences are encoded by the nucleic acid sequences of SEQ
ID NO: 75, 77, 79, 83, 85, 87;;[noData]

and 219, 221, 223, 227, 229,
231.;[noData]

In a fourth aspect, the invention features an isolated anti-
body or antigen-binding fragment thereof that specifically
binds hPCSK9, comprising a HCDR3 and a LCDR3, wherein
HCDR3 comprises an amino acid sequence of the formula
X' X X X X X X X X X' X"
X' X' X' X' X' X' X' X' X (SEQ
IDNO:747), whereinX' isAla, X isArgorLys, X isAsp, X
is SerorIle, X isAsnorVal, X is Leu or Trp, X is Gly or
Met, X is Asn or Val, X is Phe or Tyr, X' is Asp, X" is Leu
or Met, X' is Asp or absent, X' is Tyr or absent, X' is Tyr
orabsent, X' is Tyrorabsent, X' is Tyrorabsent, X' isGly
or absent, X' is Met or absent, X' isAsp or absent, and X
is Val or absent;;[noData]

and LCDR3 comprises an amino acid
sequence of the formula X' X X X X X
X X X (SEQ ID NO:750), wherein X' is Gln or Met,
X is Gln, X is Tyror Thr, X is TyrorLeu, X is ThrorGln,
X is Thr, X is Pro, X is Tyr or Leu, and X is Thr.;[noData]

In a further embodiment, the antibody or fragment thereof
further comprise a HCDRI sequence of the formula
X' X X X X X X X (SEQ ID NO:745),
wherein X' is Gly, X is Phe, X is Thr, X is Phe, X is Ser or
Asn, X is SerorAsn, X is Tyror His, and X isAlaor Trp;;[noData]

a HCDR2 sequence of the formula X' X X X
X X X X (SEQID NO:746), whereinX' is Ile, X is
Ser orAsn, X is Gly or Gln, X is Asp or Ser, X is Gly, X is
SerorGly, X is ThrorGlu, andX is ThrorLys;;[noData]

a LCDRI
sequence of the formula X' X X X X X
X X X X X X (SEQ ID NO:748) wherein
X' is Gln, X is Ser, X isVal orLeu, X is Leu, X is His or
Tyr, X isArgorSer, X is SerorAsn, X isAsnorGly, X is
Asn, X' is Arg or Asn, X" is Asn or Tyr, and X' is Phe or
absent;;[noData]

a LCDR2 sequence of the formula X' X X
(SEQ ID NO:749) wherein X' is Trp or Leu, X is Ala or Gly,
and X is Ser.;[noData]

FIG.;[noData]

1 shows the sequence alignment of heavy
and light chain variable regions for 316P and 300N mAbs.;[noData]

In a fifth aspect, the invention features a human anti-
PCSK9 antibody or antigen-binding fragment of an antibody
comprising a heavy chain variable region (HCVR) encoded
by nucleotide sequence segments derived from V~, Dem and J~
germline sequences, and a light chain variable region
(LCVR) encoded by nucleotide sequence segments derived
from V~ and J~ germline sequences, wherein the germline
sequences are (a) V~ gene segment 3-23, D~ gene segment
7-27, J~ gene segment 2, V~ gene segment 4-1 and J~ gene
segment 2;;[noData]

or (b) V~ gene segment 3-7, D~ gene segment 2-8,
J~ gene segment 6, V~ gene segment 2-28 and J~ gene seg-
ment 4.;[noData]

In a sixth aspect, the invention features an antibody or
antigen-binding fragment thereof that binds to a PCSK9 pro-
tein of SEQ ID NO:755, wherein the binding of the antibody
or fragment thereof to a variant PCSK9 protein is less than
50% of the binding between the antibody or fragment thereof
and the PCSK9 protein of SEQ ID NO:755.;[noData]

In specific
embodiment, the antibody or fragment thereof binds to the
variant PCSK9 protein with a binding affinity (K~) which is
less than about 50%, less than about 60%, less than about
5
10
15
20
25
30
35
40
45
50
55
60
65
70%, less than about 80%, less than about 90% or less than
about 95% compared to the binding to PCSK9 (SEQ ID
NO:755).;[noData]

In one embodiment, the variant PCSK9 protein comprises
at least one mutation at position 238 of SEQ ID NO:755.;[noData]

In a
more specific embodiment, the mutation is D238R.;[noData]

In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 90% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at residue 238.;[noData]

In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 80% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at one or more of
residue 153, 159, 238 and 343.;[noData]

In a more specific embodi-
ment, the mutation is one of S153R, E159R, D238R and
D343R.;[noData]

In one embodiment, the variant PCSK9 protein comprises
at least one mutation at position 366 of SEQ ID NO:755.;[noData]

In a
more specific embodiment, the mutation is E366K.;[noData]

In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 95% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at residue 366.;[noData]

In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 90% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at one or more of
residue 147, 366 and 380.;[noData]

In a more specific embodiment, the
mutation is one ofS147F,E366Kand V380M.;[noData]

In one embodi-
ment, the antibody or antibody fragment binding affinity for
the variant PCSK9 protein is at least 80% less relative to the
wildtype protein of SEQ ID NO:755, wherein the variant
protein comprises a mutation at one or more of residue 147,
366 and 380.;[noData]

In a more specific embodiment, the mutation is
one of S147F, E366K and V380M.;[noData]

The invention encompasses anti-PCSK9 antibodies having
a modified glycosylation pattern.;[noData]

In some applications, modi-
fication to remove undesirable glycosylation sites may be
useful, or, removal of a fucose moiety to increase antibody
dependent cellular cytotoxicity (ADCC) function (see Shield
et al.;[noData]

(2002) JBC 277:26733).;[noData]

In other applications, modifi-
cation of galactosylation can be made in order to modify
complement dependent cytotoxicity (CDC).;[noData]

In a seventh aspect, the invention features a pharmaceutical
composition comprising a recombinant human antibody or
fragment thereof which specifically binds hPCSK9 and a
pharmaceutically acceptable carrier.;[noData]

In one embodiment, the
invention features a composition which is a combination ofan
antibody or antigen-binding fragment of an antibody of the
invention, and a second therapeutic agent.;[noData]

The second thera-
peutic agent may be any agent that is advantageously com-
bined with the antibody or fragment thereof of the invention,
for example, an agent capable of inducing a cellular depletion
of cholesterol synthesis by inhibiting 3-hydroxy-3-methyl-
glutaryl (HMG)-coenzyme A (CoA) reductase, such as, for
example, cerovastatin, atorvastatin, simvastatin, pitavastatin,
rosuvastatin, fluvastatin, lovastatin, pravastatin, etc.;[noData]

capable
of inhibiting cholesterol uptake and or bile acid re-absorp-
tion;;[noData]

capable of increasing lipoprotein catabolism (such as
niacin);;[noData]

and/or activators of the LXR transcription factor that
plays a role in cholesterol elimination such as 22-hydroxyc-
holesterol.;[noData]

In an eighth aspect, the invention features methods for
inhibiting hPCSK9 activity using the anti-PCSK9 antibody or
antigen-binding portion of the antibody of the invention,
wherein the therapeutic methods comprise administering a
US 8,357,371 B2
therapeutically effective amount of a pharmaceutical compo-
sition comprising an antibody or antigen-binding fragment of
an antibody of the invention.;[noData]

The disorder treated is any
disease or condition which is improved, ameliorated, inhib-
ited or prevented by removal, inhibition or reduction of
PCSK9 activity.;[noData]

Specific populations treatable by the thera-
peutic methods of the invention include subjects indicated for
LDL apheresis, subjects with PCSK9-activating mutations
(gain of function mutations, "GOF"), subjects with heterozy-
gous Familial Hypercholesterolemia (heFH);;[noData]

subjects with
primary hypercholesterolemia who are statin intolerant or
statin uncontrolled;;[noData]

and subjects at risk for developing hyper-
cholesterolemia who may be preventably treated.;[noData]

Other indi-
cations include dyslipidemia associated with secondary
causes such as Type 2 diabetes mellitus, cholestatic liver
diseases (primary biliary cirrhosis), nephrotic syndrome,
hypothyroidism, obesity;;[noData]

and the prevention and treatment of
atherosclerosis and cardiovascular diseases.;[noData]

In specific embodiments ofthe method ofthe invention, the
anti-hPCSK9 antibody or antibody fragment of the invention
is useful to reduce elevated total cholesterol, non-HDL cho-
lesterol, LDL cholesterol, and/or apolipoprotein B (apolipo-
protein B100).;[noData]

The antibody or antigen-binding fragment of the invention
may be used alone or in combination with a second agent, for
example, an HMG-CoA reductase inhibitor and/or other lipid
lowering drugs.;[noData]

Other embodiments will become apparent from a review of
the ensuing detailed description.;[noData]

